These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

963 related items for PubMed ID: 27429374

  • 1. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK, Chang CK, Peng CH.
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial.
    Zhao M, Zhang F, Chen Y, Dai H, Qu J, Dong C, Kang X, Liu Y, Yang L, Li Y, Zhou P, Pan CT, Zhang L, Liu P, Zhou H, Jiao X, Xiong Y, Tian R, Lu Y, Yu X, Li X.
    JAMA Ophthalmol; 2015 Mar; 133(3):333-40. PubMed ID: 25555191
    [Abstract] [Full Text] [Related]

  • 7. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
    Chan WM, Lai TY, Lai RY, Liu DT, Lam DS.
    Ophthalmology; 2008 Oct; 115(10):1756-65. PubMed ID: 18538401
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial.
    Reibaldi M, Cardascia N, Longo A, Furino C, Avitabile T, Faro S, Sanfilippo M, Russo A, Uva MG, Munno F, Cannemi V, Zagari M, Boscia F.
    Am J Ophthalmol; 2010 Feb; 149(2):307-315.e2. PubMed ID: 19896635
    [Abstract] [Full Text] [Related]

  • 11. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
    Liu Y, Li L, Xu G, Wang W.
    Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
    [Abstract] [Full Text] [Related]

  • 12. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy.
    Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF.
    Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V, Vysloužilová D, Uher M.
    Semin Ophthalmol; 2018 Sep; 33(5):690-699. PubMed ID: 29252091
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.
    Fujita K, Yuzawa M, Mori R.
    Retina; 2011 Apr; 31(4):772-8. PubMed ID: 20890236
    [Abstract] [Full Text] [Related]

  • 19. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V, Purtskhvanidze K, Roider J.
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [Abstract] [Full Text] [Related]

  • 20. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Gulkas S, Sahin O.
    Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.